Document:

Exhibit 10.7

 

FORM OF INDEMNIFICATION AGREEMENT

 

THIS
INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of [·],
2021.

 

BETWEEN:

 

(1)           PEPPERLIME
HEALTH ACQUISITION CORPORATION, an exempted company incorporated under the laws of the Cayman Islands with its registered office at
PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (the “Company”); and

 

(2)           [•]
(“Indemnitee”).

 

WHEREAS:

 

(A)          Highly
competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless
they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions
against them arising out of their service to and activities on behalf of such corporations;

 

(B)          The
board of directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals
as directors and officers, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect
such persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary
and widespread practice among corporations and other business enterprises, the Company believes that, given current market conditions
and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors,
officers and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming
litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise
itself. The amended and restated memorandum and articles of association of the Company (the “Articles”) provide for
the indemnification of the officers and directors of the Company. The Articles expressly provide that the indemnification provisions set
forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the Board,
officers and other persons with respect to indemnification, hold harmless, exoneration, advancement and reimbursement rights;

 

(C)          The
uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

 

(D)          The
Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the
Company’s shareholders and that the Company should act to assure such persons that there will be increased certainty of such protection
in the future;

 

(E)           It
is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, hold harmless, exonerate and to advance
expenses on behalf of, such persons to the fullest extent permitted by applicable law and the Articles so that they will serve or continue
to serve the Company free from undue concern that they will not be so protected against liabilities;

 

     

     

    

 

(F)           This
Agreement is a supplement to and in furtherance of the Articles and any resolutions adopted pursuant thereto, and shall not be deemed
a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and

 

(G)           Indemnitee
may not be willing to serve as an officer or director, advisor or in another capacity without adequate protection, and the Company desires
Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf
of the Company on the condition that Indemnitee be so indemnified.

 

NOW,
THEREFORE, in consideration of the premises and the covenants contained herein and subject to the provisions of the letter
agreement dated as of [•], 2021 between the Company, Indemnitee and other parties thereto, the Company and Indemnitee do hereby
covenant and agree as follows:

 

TERMS AND CONDITIONS

 

1.            Services
to the Company. In consideration of the Company’s covenants and obligations hereunder, Indemnitee will serve or continue
to serve as an officer, director, key employee or in any other capacity of the Company, as applicable, for so long as Indemnitee is duly
elected or appointed or until Indemnitee tenders Indemnitee’s resignation or until Indemnitee is removed. The foregoing notwithstanding,
this Agreement shall continue in full force and effect after Indemnitee has ceased to serve as a director, officer, key employee or in
any other capacity of the Company, in each case as provided in Section 17. This Agreement, however, shall not impose any obligation
on Indemnitee or the Company to continue Indemnitee’s service to the Company beyond any period otherwise required by law or by
other agreements or commitments of the parties, if any.

 

2.            Definitions.
As used in this Agreement:

 

2.1           References
to “agent” shall mean any person who is or was a director, officer or employee of the Company or a subsidiary of the Company
or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer,
employee, advisor, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or
other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.

 

2.2           The
terms “Beneficial Owner” and “Beneficial Ownership” shall have the meanings set forth in Rule 13d-3
promulgated under the Exchange Act (as defined below) as in effect on the date hereof.

 

2.3           “Cayman
Court” shall mean the courts in the Cayman Islands.

 

    2 

     

    

 

2.4            A
 “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of
the following events:

 

(a)           Acquisition
of Shares by Third Party. Other than an affiliate of PepperOne LLC (the “Sponsor”), any Person (as defined below) is or
becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined
voting power of the Company’s then outstanding securities entitled to vote generally in the election of directors, unless (1) the
change in the relative Beneficial Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate
number of outstanding shares entitled to vote generally in the election of directors, or (2) such acquisition was approved in advance
by the Continuing Directors (as defined below) and such acquisition would not constitute a Change in Control under part (c) of this
definition;

 

(b)           Change
in Board of Directors. Individuals who, as of the date hereof, constitute the Board, and any new director whose election by the Board
or nomination for election by the Company’s shareholders was approved by a vote of at least two-thirds of the directors then still
in office who were directors on the date hereof or whose election or nomination for election was previously so approved (collectively,
the “Continuing Directors”), cease for any reason to constitute at least a majority of the members of the Board;

 

(c)           Corporate
Transactions. The effective date of a merger, share exchange, asset acquisition, share purchase, reorganization or similar business
combination or entities, involving the Company and one or more businesses (a “Business Combination”), in each case,
unless, following such Business Combination: (1) all or substantially all of the individuals and entities who were the Beneficial
Owners of securities entitled to vote generally in the election of directors immediately prior to such Business Combination beneficially
own, directly or indirectly, more than fifty-one percent (51%) of the combined voting power of the then outstanding securities of the
Company entitled to vote generally in the election of directors resulting from such Business Combination (including, without limitation,
a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either
directly or through one or more Subsidiaries (as defined below)) in substantially the same proportions as their ownership immediately
prior to such Business Combination, of the securities entitled to vote generally in the election of directors; (2) other than the
Sponsor or any of its affiliates, no Person (excluding any corporation resulting from such Business Combination) is the Beneficial Owner,
directly or indirectly, of fifteen percent (15%) or more of the combined voting power of the then outstanding securities entitled to vote
generally in the election of directors of the surviving corporation except to the extent that such ownership existed prior to the Business
Combination; and (3) at least a majority of the Board of Directors of the corporation resulting from such Business Combination were
Continuing Directors at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for
such Business Combination;

 

(d)           Liquidation.
The approval by the shareholders of the Company of a complete liquidation or dissolution of the Company or an agreement or series of agreements
for the sale or disposition by the Company of all or substantially all of the Company’s assets, other than factoring the Company’s
current receivables or escrows due (or, if such shareholder approval is not required, the decision by the Board to proceed with such a
liquidation, sale, or disposition in one transaction or a series of related transactions); or

 

(e)           Other
Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A
of Regulation 14A (or any successor rule) (or a response to any similar item on any similar schedule or form) promulgated under the Exchange
Act (as defined below), whether or not the Company is then subject to such reporting requirement.

 

    3 

     

    

 

2.5           “Corporate
Status” describes the status of a person who is or was a director, director nominee, officer, trustee, general partner, manager,
managing member, fiduciary, employee or agent of the Company or of any other Enterprise (as defined below) which such person is or was
serving at the request of the Company.

 

2.6           “Disinterested
Director” shall mean a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect
of which indemnification is sought by Indemnitee.

 

2.7           “Enterprise”
shall mean the Company and any other corporation, constituent corporation (including any constituent of a constituent) absorbed in a consolidation
or merger to which the Company (or any of its wholly owned subsidiaries) is a party, limited liability company, partnership, joint venture,
trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer,
trustee, manager, general partner, managing member, fiduciary, employee or agent.

 

2.8           “Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended.

 

2.9           “Expenses”
shall include all direct and indirect costs, fees and expenses of any type or nature whatsoever, including, without limitation, all reasonable
attorneys’ fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private
investigators and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees,
fax transmission charges, secretarial services and all other disbursements, obligations or expenses in connection with prosecuting, defending,
preparing to prosecute or defend, investigating, being or preparing to be a witness in, settlement or appeal of, or otherwise participating
in, a Proceeding (as defined below), including reasonable compensation for time spent by Indemnitee for which he or she is not otherwise
compensated by the Company or any third party. Expenses also shall include Expenses incurred in connection with any appeal resulting from
any Proceeding (as defined below), including without limitation the principal, premium, security for, and other costs relating to any
cost bond, supersede as bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement
by Indemnitee or the amount of judgments or fines against Indemnitee.

 

2.10         References
to “fines” shall include any excise tax assessed on Indemnitee with respect to any employee benefit plan; references
to “serving at the request of the Company” shall include any service as a director, officer, employee, agent or fiduciary
of the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to
an employee benefit plan, its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably
believed to be in the best interests of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed
to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

    4 

     

    

 

2.11         “Independent
Counsel” shall mean a law firm or a member of a law firm with significant experience in matters of corporate law and that neither
presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to
either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar
indemnification agreements); or (ii) any other party to the Proceeding (as defined below) giving rise to a claim for indemnification
hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable
standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee
in an action to determine Indemnitee’s rights under this Agreement.

 

2.12         The
term “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act as in effect
on the date hereof; provided, however, that “Person” shall exclude: (i) the Company; (ii) any Subsidiaries
(as defined below) of the Company; (iii) any employment benefit plan of the Company or of a Subsidiary (as defined below) of the
Company or of any corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions
as their ownership of shares of the Company; and (iv) any trustee or other fiduciary holding securities under an employee benefit
plan of the Company or of a Subsidiary (as defined below) of the Company or of a corporation owned directly or indirectly by the shareholders
of the Company in substantially the same proportions as their ownership of shares of the Company.

 

2.13         The
term “Proceeding” shall include any threatened, pending or completed action, suit, arbitration, mediation, alternate
dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened, pending or completed proceeding,
whether brought in the right of the Company or otherwise and whether of a civil (including intentional or unintentional tort claims),
criminal, administrative, or investigative or related nature, in which Indemnitee was, is, will or might be involved as a party or otherwise
by reason of the fact that Indemnitee is or was a director or officer or key employee of the Company, by reason of any action (or failure
to act) taken by Indemnitee or of any action (or failure to act) on Indemnitee’s part while acting as a director, director nominee
or officer or key employee of the Company, or by reason of the fact that Indemnitee is or was serving at the request of the Company as
a director, director nominee or officer, trustee, general partner, manager, managing member, fiduciary, employee or agent of any other
Enterprise, in each case, whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification,
reimbursement, or advancement of expenses can be provided under this Agreement but shall not include any Enforcement Proceeding pursuant
to Section 14.

 

2.14         “serving
at the request of the Company” shall include any service as a director, officer, employee, agent or fiduciary of the Company
which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee benefit
plan, its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in
the best interests of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in
a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

2.15         The
term “Subsidiary,” with respect to any Person, shall mean any corporation, limited liability company, partnership,
joint venture, trust or other entity of which a majority of the voting power of the voting equity securities or equity interest is owned,
directly or indirectly, by that Person.

 

    5 

     

    

 

3.            Indemnity
in third-party proceedings. To the fullest extent permitted by applicable law and the Articles, the Company shall indemnify, hold
harmless and exonerate Indemnitee in accordance with the provisions of this Section 3 if Indemnitee was, is, or is threatened to
be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding, other than a Proceeding by or in the right
of the Company to procure a judgment in its favor by reason of the Indemnitees’s Corporate Status. Pursuant to this Section 3, Indemnitee
shall be indemnified, held harmless and exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in
settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses,
judgments, liabilities, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on Indemnitee’s
behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable
cause to believe that Indemnitee’s conduct was unlawful.

 

4.            Indemnity
in proceedings by or in the right of the Company. To the fullest extent permitted by applicable law and the Articles, the Company
shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section 4 if Indemnitee was, is,
or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding by or in the right of
the Company to procure a judgment in its favor by reason of the Indemnitee’s Corporate Status. Pursuant to this Section 4, Indemnitee
shall be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s
behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company. No indemnification, hold harmless or exoneration for
Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally
adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to the extent that any court in which the
Proceeding was brought or the Cayman Court shall determine upon application that, despite the adjudication of liability but in view of
all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification, to be held harmless or to exoneration.

 

5.            Indemnification
for expenses of a party who is wholly or partly successful. Notwithstanding any other provisions of this Agreement except for Section 27,
to the extent that Indemnitee was or is, by reason of the Indemnitee’s Corporate Status, a party to (or a participant in) and is
successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the
Company shall, to the fullest extent permitted by applicable law and the Articles, indemnify, hold harmless and exonerate Indemnitee
against all Expenses actually and reasonably incurred by Indemnitee in connection therewith. If Indemnitee is not wholly successful in
such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such
Proceeding, the Company shall, to the fullest extent permitted by applicable law and the Articles, indemnify, hold harmless and exonerate
Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with each
such successfully resolved claim, issue or matter. If Indemnitee is not wholly successful in defense of such Proceeding, the Company
also shall, to the fullest extent permitted by applicable law and the Articles, indemnify, hold harmless and exonerate Indemnitee against
all Expenses reasonably incurred in connection with a claim, issue or matter related to any claim, issue, or matter on which Indemnitee
was successful. For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding
by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

    6 

     

    

 

6.            Indemnification
for expenses of a witness. Notwithstanding any other provision of this Agreement except for Section 27, to the extent that Indemnitee
is, by reason of Indemnitee’s Corporate Status, a witness or deponent in any Proceeding to which Indemnitee was or is not a party
or threatened to be made a party, Indemnitee shall, to the fullest extent permitted by applicable law and the Articles, be indemnified,
held harmless and exonerated against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection
therewith.

 

7.     Additional
indemnification, hold harmless and exoneration rights. 7.1     Notwithstanding
any limitation in Section 3, 4, or 5, except for Section 27, the Company shall, to the fullest extent permitted by applicable
law and the Articles, indemnify, hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to
any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments,
liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in
connection with or in respect of such Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement) actually and
reasonably incurred by Indemnitee in connection with the Proceeding. No indemnification, hold harmless or exoneration rights shall be
available under this Section 7.1 on account of Indemnitee’s conduct which constitutes a breach of Indemnitee’s duties
to the Company or its shareholders or is an act or omission not in good faith or which involves intentional misconduct or a knowing violation
of applicable law.

 

7.2            Notwithstanding
any limitation in Section 3, 4, 5 or 7.1, except for Section 27, the Company shall, to the fullest extent permitted by applicable
law and the Articles, indemnify, hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to
any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments,
liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in
connection with or in respect of such Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement) actually and
reasonably incurred by Indemnitee in connection with the Proceeding.

 

8.            Contribution
in the event of joint liability.

 

8.1            To
the fullest extent permissible under applicable law and the Articles, if the indemnification, hold harmless and/or exoneration rights
provided for in this Agreement are unavailable to Indemnitee in whole or in part for any reason whatsoever, the Company, in lieu of indemnifying,
holding harmless or exonerating Indemnitee, shall pay, in the first instance, the entire amount incurred by Indemnitee, whether for judgments,
liabilities, fines, penalties, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding without
requiring Indemnitee to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have
at any time against Indemnitee.

 

    7 

     

    

 

8.2            The
Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined
in such Proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.

 

8.3            The
Company hereby agrees to fully indemnify, hold harmless and exonerate Indemnitee from any claims for contribution which may be brought
by officers, directors or employees of the Company other than Indemnitee who may be jointly liable with Indemnitee.

 

9.            Exclusions.
Notwithstanding any provision in this Agreement except for Section 27, the Company shall not be obligated under this Agreement to
make any indemnification, advance expenses, hold harmless or exoneration payment in connection with any claim made against Indemnitee:

 

9.1            for
which payment has actually been received by or on behalf of Indemnitee under any insurance policy, contract, agreement or other indemnity
or advancement provision or otherwise, except with respect to any excess beyond the amount actually received under any insurance policy,
contract, agreement, other indemnity or advancement provision or otherwise;

 

9.2            for
an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the
meaning of Section 16(b) of the Exchange Act (or any successor rule) or similar provisions of state statutory law or common
law; or

 

9.3            except
as otherwise provided in Sections 14.5 and 14.6 hereof, prior to a Change in Control, in connection with any Proceeding (or any part of
any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the
Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of
any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, advance of expenses, hold harmless or exoneration
payment, in its sole discretion, pursuant to the powers vested in the Company under applicable law. Indemnitee shall seek payments or
advances from the Company only to the extent that such payments or advances are unavailable from any insurance policy of the Company covering
Indemnitee.

 

10.            Advances
of expenses; defense of claim.

 

10.1            Notwithstanding
any provision of this Agreement to the contrary except for Section 27, and to the fullest extent not prohibited by applicable law
and the Articles, the Company shall pay the Expenses incurred by Indemnitee (or reasonably expected by Indemnitee to be incurred by Indemnitee
within three months) in connection with any Proceeding within ten (10) days after the receipt by the Company of a statement or statements
requesting such advances from time to time, prior to the final disposition of any Proceeding. Advances shall, to the fullest extent permitted
by law, be unsecured and interest free. Advances shall, to the fullest extent permitted by law, be made without regard to Indemnitee’s
ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to be indemnified, held harmless or exonerated
under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing a Proceeding to
enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances
claimed. To the fullest extent required by applicable law, such payments of Expenses in advance of the final disposition of the Proceeding
shall be made only upon the Company’s receipt of an undertaking, by or on behalf of Indemnitee, to repay the advance to the extent
that it is ultimately determined that Indemnitee is not entitled to be indemnified, held harmless or exonerated by the Company under the
provisions of this Agreement, the Articles, applicable law or otherwise. This Section 10.1 shall not apply to any claim made by Indemnitee
for which an indemnification, advance of expenses, hold harmless or exoneration payment is excluded pursuant to Section 9.

 

    8 

     

    

 

 10.2            The Company will be entitled to participate in the Proceeding at its own expense.

 

10.3            The
Company shall not settle any action, claim or Proceeding (in whole or in part) which would impose any Expense, judgment, liability, fine,
penalty or limitation on Indemnitee without Indemnitee’s prior written consent.

 

11.            Procedure
for notification and application for indemnification.

 

11.1            Indemnitee
agrees to promptly notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information
or other document relating to any Proceeding, claim, issue or matter therein which may be subject to indemnification, hold harmless or
exoneration rights, or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve
the Company of any obligation which it may have to Indemnitee under this Agreement, or otherwise.

 

11.2            Indemnitee
may deliver to the Company a written application to indemnify, hold harmless or exonerate Indemnitee in accordance with this Agreement.
Such application(s) may be delivered from time to time and at such time(s) as Indemnitee deems appropriate in Indemnitee’s
sole discretion. Following such a written application for indemnification by Indemnitee, Indemnitee’s entitlement to indemnification
shall be determined according to Section 12.1 of this Agreement.

 

12.            Procedure
upon application for indemnification.

 

12.1            A
determination, if required by applicable law, with respect to Indemnitee’s entitlement to indemnification shall be made in the specific
case by one of the following methods, which shall be at the election of Indemnitee: (i) by a majority vote of the Disinterested Directors,
even though less than a quorum of the Board; (ii) by Independent Counsel in a written opinion to the Board, a copy of which shall
be delivered to Indemnitee; or (iii) by vote of the shareholders by ordinary resolution. The Company will promptly advise Indemnitee
in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any
reason or basis for which indemnification has been denied. If it is so determined that Indemnitee is entitled to indemnification, payment
to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall reasonably cooperate with the person,
persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to
such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected
from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses
(including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making
such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification)
and the Company hereby agrees to indemnify and to hold Indemnitee harmless therefrom.

 

    9 

     

    

 

12.2            In
the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12.1 hereof,
the Independent Counsel shall be selected as provided in this Section 12.2. The Independent Counsel shall be selected by Indemnitee
(unless Indemnitee shall request that such selection be made by the Board), and Indemnitee shall give written notice to the Company advising
it of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected meets the requirements
of “Independent Counsel” as defined in Section 2 of this Agreement. If the Independent Counsel is selected by the Board,
the Company shall give written notice to Indemnitee advising Indemnitee of the identity of the Independent Counsel so selected and certifying
that the Independent Counsel so selected meets the requirements of “Independent Counsel” as defined in Section 2 of this
Agreement. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice
of selection shall have been received, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection;
provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does
not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall
set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act
as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent
Counsel unless and until such objection is withdrawn or a court of competent jurisdiction has determined that such objection is without
merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification pursuant to Section 11.2
hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Cayman
Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent
Counsel and/or for the appointment as Independent Counsel of a person selected by the Cayman Court, and the person with respect to whom
all objections are so resolved or the person or law firm so appointed shall act as Independent Counsel under Section 12.1 hereof.
Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14.1 of this Agreement, Independent
Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional
conduct then prevailing).

 

12.3            The
Company agrees to pay the reasonable fees and expenses of Independent Counsel and to fully indemnify and hold harmless such Independent
Counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or such Independent
Counsel’s engagement pursuant hereto.

 

13.            Presumptions
and effect of certain proceedings.

 

13.1            In
making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination
shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification
in accordance with Section 11.2 of this Agreement, and the Company shall have the burden of proof to overcome that presumption in
connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of
the Company (including by its Disinterested Directors or Independent Counsel) to have made a determination prior to the commencement of
any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard
of conduct, nor an actual determination by the Company (including by its Disinterested Directors or Independent Counsel) that Indemnitee
has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met
the applicable standard of conduct.

 

    10 

     

    

 

13.2            If
the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled
to indemnification shall not have made a determination within thirty (30) days after receipt by the Company of the request therefor, the
requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall, to the fullest extent
permitted by applicable law and the Articles, be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material
fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the
request for indemnification, or (ii) a final judicial determination that any or all such indemnification is expressly prohibited
under applicable law; provided, however, that such 30-day period may be extended for a reasonable time, not to exceed an
additional fifteen (15) days, if the person, persons or entity making the determination with respect to entitlement to indemnification
in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto.

 

13.3            The
termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of
nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the
right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee
had reasonable cause to believe that Indemnitee’s conduct was unlawful.

 

13.4            For
purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action
is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee
by the directors, managers, managing members, or officers of the Enterprise in the course of their duties, or on the advice of legal counsel
for the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing member or on
information or records given or reports made to the Enterprise, its Board, any committee of the Board or any director, trustee, general
partner, manager or managing member by an independent certified public accountant or by an appraiser or other expert selected by the Enterprise,
its Board, any committee of the Board or any director, trustee, general partner, manager or managing member. The provisions of this Section 13.4
shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed or found to have
met the applicable standard of conduct set forth in this Agreement.

 

13.5            The
knowledge and/or actions, or failure to act, of any other director, officer, trustee, partner, manager, managing member, fiduciary, agent
or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

 

    11 

     

    

 

14.            Remedies
of indemnitee.

 

14.1            In
the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification
under this Agreement, (ii) advancement of Expenses, to the fullest extent permitted by applicable law and the Articles, is not timely
made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made
pursuant to Section 12.1 of this Agreement within thirty (30) days after receipt by the Company of the request for indemnification,
(iv) payment of indemnification is not made pursuant to Sections 5, 6, 7 or the last sentence of Section 12.1 of this Agreement
within ten (10) days after receipt by the Company of a written request therefor, (v) a contribution payment is not made in a
timely manner pursuant to Section 8 of this Agreement, (vi) payment of indemnification pursuant to Section 3 or 4 of this
Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or
(vii) payment to Indemnitee pursuant to any hold harmless or exoneration rights under this Agreement or otherwise is not made within
ten (10) days after receipt by the Company of a written request therefor, Indemnitee shall be entitled to an adjudication by
the Cayman Court to such indemnification, hold harmless, exoneration, contribution or advancement rights. Alternatively, Indemnitee,
at Indemnitee’s option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration
Rules and Mediation Procedures of the American Arbitration Association. Except as set forth herein, the provisions of Cayman Islands
law (without regard to its conflict of laws rules) shall apply to any such arbitration. The Company shall not oppose Indemnitee’s
right to seek any such adjudication or award in arbitration. Such adjudication or arbitration proceeding is referred to herein as “Enforcement
Proceeding”.

 

14.2            In
the event that a determination shall have been made pursuant to Section 12.1 of this Agreement that Indemnitee is not entitled to
indemnification, any Enforcement Proceeding shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee
shall not be prejudiced by reason of that adverse determination. In Enforcement Proceeding, Indemnitee shall be presumed to be entitled
to be indemnified, held harmless, exonerated and to receive advances of Expenses under this Agreement and the Company shall have the burden
of proving Indemnitee is not entitled to be indemnified, held harmless, exonerated and to receive advances of Expenses, as the case may
be, and the Company may not refer to or introduce into evidence any determination pursuant to Section 12.1 of this Agreement adverse
to Indemnitee for any purpose. If Indemnitee commences an Enforcement Proceeding, Indemnitee shall not be required to reimburse the
Company for any advances pursuant to Section 10 until a final determination is made with respect to Indemnitee’s entitlement
to indemnification (as to which all rights of appeal have been exhausted or lapsed).

 

14.3            If
a determination shall have been made pursuant to Section 12.1 of this Agreement that Indemnitee is entitled to indemnification, the
Company shall be bound by such determination in Enforcement Proceeding, absent (i) a misstatement by Indemnitee of a material fact,
or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request
for indemnification, or (ii) a prohibition of such indemnification under applicable law.

 

    12 

     

    

 

14.4            The
Company shall be precluded from asserting in Enforcement Proceeding that the procedures and presumptions of this Agreement are not valid,
binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions
of this Agreement.

 

14.5            The
Company shall indemnify and hold harmless Indemnitee to the fullest extent permitted by applicable law and the Articles against all Expenses
(assuming for purpose of this sentence that all references to a Proceeding in the definition of Expenses were references to an Enforcement
Proceeding) and, if requested by Indemnitee, shall (within ten (10) days after the Company’s receipt of such written request)
pay to Indemnitee, to the fullest extent permitted by applicable law and the Articles, such Expenses which are incurred by Indemnitee
in connection with any Enforcement Proceeding brought by Indemnitee (i) to enforce Indemnitee’s rights under, or to recover
damages for breach of, this Agreement or any other indemnification, hold harmless, exoneration, advancement or contribution agreement
or provision of the Articles now or hereafter in effect; or (ii) for recovery or advances under any insurance policy maintained by
any person for the benefit of Indemnitee, regardless of the outcome and whether Indemnitee ultimately is determined to be entitled to
such indemnification, hold harmless or exoneration right, advancement, contribution or insurance recovery, as the case may be (unless
such Enforcement Proceeding was not brought by Indemnitee in good faith).

 

14.6            Interest
shall be paid by the Company to Indemnitee at a rate to be agreed between the Company and the Indemnitee for amounts which the Company
indemnifies, holds harmless or exonerates or advances, or is obliged to indemnify, hold harmless or exonerate or advance for the period
commencing with the date on which Indemnitee requests indemnification, to be held harmless, exonerated, contribution, reimbursement or
advancement of any Expenses and ending with the date on which such payment is made to Indemnitee by the Company.

 

15.            Security.
Notwithstanding anything herein to the contrary except for Section 27, to the extent requested by Indemnitee and approved by the
Board, the Company may at any time and from time to time provide security to Indemnitee for the Company’s obligations hereunder
through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not
be revoked or released without the prior written consent of Indemnitee.

 

16.            Non-exclusivity;
survival of rights; insurance; subrogation; priority of obligations

 

16.1            The
rights of Indemnitee as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time
be entitled under applicable law, the Articles, any agreement, a vote of shareholders or a resolution of directors, or otherwise. No amendment,
alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement
in respect of any Proceeding (regardless of when such Proceeding is first threatened, commenced or completed) or claim, issue or matter
therein arising out of, or related to, any action taken or omitted by such Indemnitee in Indemnitee’s Corporate Status prior to
such amendment, alteration or repeals, except as may otherwise be expressly set forth in such amendment, alternation or repeal and mutually
agreed by Indemnitee and the Company. To the extent that a change in applicable law, whether by statute or judicial decision, permits
greater indemnification, hold harmless or exoneration rights or advancement of Expenses than would be afforded currently under the Articles
or this Agreement, then this Agreement (without any further action by the parties hereto) shall automatically be deemed to be amended
to require that the Company indemnify Indemnitee to the fullest extent permitted by law. No right or remedy herein conferred is intended
to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right
and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or
remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 

    13 

     

    

 

16.2            The
Articles permit the Company to purchase and maintain insurance or furnish similar protection or make other arrangements including, but
not limited to, providing a trust fund, letter of credit, or surety bond (“Indemnification Arrangements”) on behalf
of Indemnitee against any liability asserted against Indemnitee or incurred by or on behalf of Indemnitee or in such capacity as a director,
officer, employee or agent of the Company, or arising out of Indemnitee’s status as such, whether or not the Company would have
the power to indemnify Indemnitee against such liability under the provisions of this Agreement, as it may then be in effect. The purchase,
establishment, and maintenance of any such Indemnification Arrangement shall not in any way limit or affect the rights and obligations
of the Company or of Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement
by the Company and Indemnitee shall not in any way limit or affect the rights and obligations of the Company or the other party or parties
thereto under any such Indemnification Arrangement.

 

16.3            To
the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, trustees,
partners, managers, managing members, fiduciaries, employees, or agents of the Company or of any other Enterprise which such person serves
at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the
maximum extent of the coverage available for any such director, officer, trustee, partner, manager, managing member, fiduciary, employee
or agent under such policy or policies. If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee
is a party or a participant (as a witness, deponent or otherwise), the Company has director and officer liability insurance in effect,
the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective
policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee,
all amounts payable as a result of such Proceeding in accordance with the terms of such policies.

 

16.4            In
the event of any payment under this Agreement, the Company, to the fullest extent permitted by law, shall be subrogated to the extent
of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to
secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

16.5            The
Company’s obligation to indemnify, hold harmless, exonerate or advance Expenses hereunder to Indemnitee who is or was serving at
the request of the Company as a director, officer, trustee, partner, manager, managing member, fiduciary, employee or agent of any other
Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification, hold harmless or exoneration payments or
advancement of expenses from such Enterprise. Notwithstanding any other provision of this Agreement to the contrary except for Section 27,
(i) Indemnitee shall have no obligation to reduce, offset, allocate, pursue or apportion any indemnification, hold harmless, exoneration,
advancement, contribution or insurance coverage among multiple parties possessing such duties to Indemnitee prior to the Company’s
satisfaction and performance of all its obligations under this Agreement, and (ii) the Company shall perform fully its obligations
under this Agreement without regard to whether Indemnitee holds, may pursue or has pursued any indemnification, advancement, hold harmless,
exoneration, contribution or insurance coverage rights against any person or entity other than the Company.

 

    14 

     

    

 

16.6            [To
the extent Indemnitee has rights to indemnification, advancement of expenses and/or insurance provided by the Sponsor or its affiliates
as applicable, (i) the Company shall be the indemnitor of first resort (i.e., that its obligations to Indemnitee are primary and
any obligation of the Sponsor or its affiliates, as applicable, to advance expenses or to provide indemnification for the same expenses
or liabilities incurred by Indemnitee are secondary), (ii) the Company shall be required to advance the full amount of expenses
incurred by Indemnitee and shall be liable for the full amount of all claims, liabilities, damages, losses, costs and expenses (including
amounts paid in satisfaction of judgments, in compromises and settlements, as fines and penalties and legal or other costs and reasonable
expenses of investigating or defending against any claim or alleged claim) to the extent legally permitted and as required by the terms
of this Agreement, the Company’s organizational documents or other agreement, without regard to any rights Indemnitee may have
against the Sponsor or its affiliates, as applicable, and (iii) the Company irrevocably waives, relinquishes and releases the Sponsor
and its affiliates, as applicable, from any and all claims against them for contribution, subrogation or any other recovery of any kind
in respect thereof. No advancement or payment by the Sponsor or its affiliates, as applicable, on behalf of Indemnitee with respect to
any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing, and the Sponsor and its affiliates,
as applicable, shall have a right of contribution and be subrogated to the extent of such advancement or payment to all of the rights
of recovery of Indemnitee against the Company.]

 

17.            Duration
of agreement. All agreements and obligations of the Company contained herein shall continue during the period Indemnitee serves as
a director or officer of the Company or as a director, officer, trustee, partner, manager, managing member, fiduciary, employee or agent
of any other corporation, partnership, joint venture, trust, employee benefit plan or other Enterprise which Indemnitee serves at the
request of the Company and shall continue thereafter so long as Indemnitee shall be subject to any possible Proceeding or Enforcement
Proceeding (including any rights of appeal thereto) by reason of Indemnitee’s Corporate Status, whether or not Indemnitee is acting
in any such capacity at the time any liability or expense is incurred for which indemnification or advancement can be provided under
this Agreement.

 

18.            Severability.
If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the
validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any
Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is
not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the
fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to
applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions
of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any
such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed
so as to give effect to the intent manifested thereby.

 

    15 

     

    

 

19.            Enforcement
and binding effect.

 

19.1            The
Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order
to induce Indemnitee to serve as a director, officer or key employee of the Company, and the Company acknowledges that Indemnitee is relying
upon this Agreement in serving as a director, officer or key employee of the Company.

 

19.2            Without
limiting any of the rights of Indemnitee under Articles as they may be amended from time to time, this Agreement constitutes the entire
agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings,
oral, written and implied, between the parties hereto with respect to the subject matter hereof.

 

19.3            The
indemnification, hold harmless, exoneration and advancement of expenses rights provided by or granted pursuant to this Agreement shall
be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect
successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company), shall
continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or a director, officer, trustee,
general partner, manager, managing member, fiduciary, employee or agent of any other Enterprise at the Company’s request, and shall
inure to the benefit of Indemnitee and Indemnitee’s spouse, assigns, heirs, devisees, executors and administrators and other legal
representatives.

 

19.4            The
Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially
all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee,
expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to
perform if no such succession had taken place.

 

19.5            The
Company and Indemnitee agree herein that a monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable
and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree
that Indemnitee may, to the fullest extent permitted by law, enforce this Agreement by seeking, among other things, injunctive relief
and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm and that by seeking injunctive
relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which Indemnitee
may be entitled. The Company and Indemnitee further agree that Indemnitee shall, to the fullest extent permitted by law, be entitled to
such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions,
without the necessity of posting bonds or other undertaking in connection therewith. The Company acknowledges that in the absence of a
waiver, a bond or undertaking may be required of Indemnitee by a Court of competent jurisdiction and the Company hereby waives any such
requirement of such a bond or undertaking to the fullest extent permitted by law.

 

    16 

     

    

 

20.            Modification
and waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the Company
and Indemnitee. No waiver of any provision of this Agreement shall be enforceable unless in writing and signed by the party against whom
it is to be enforced. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provisions of this Agreement nor shall any waiver constitute a continuing waiver.

 

21.            Notices.
All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly
given (i) if delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed,
or (ii) mailed by certified or registered mail with postage prepaid, on the third (3rd) business day after the date on which it
is so mailed:

 

21.1         If
to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide
in writing to the Company.

 

		21.2	If to the Company, to:

PepperLime Health Acquisition Corporation

548 Market Street, Suite 97425

San Francisco, California 94104

Attn: [·]

 

		21.3	And With a copy, which shall not constitute notice, to

 

Freshfields Bruckhaus Deringer LLP

601 Lexington Avenue

New York, New York 10022

Attn: Valerie Ford Jacob, Esq. or to any other address as may have been furnished to Indemnitee in writing
by the Company.

 

22.          Applicable
law and consent to jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and
enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to
any arbitration commenced by Indemnitee pursuant to Section 14.1 of this Agreement, the Company and Indemnitee hereby irrevocably
and unconditionally: (a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought
only in the Delaware Court and not in any other state or federal court in the United States of America or any court in any other country;
(b) consent to submit to the exclusive jurisdiction of the Delware Court for purposes of any action or proceeding arising out of
or in connection with this Agreement; (c) waive any objection to the laying of venue of any such action or proceeding in the Delaware
Court; and (d) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delware Court
has been brought in an improper or inconvenient forum, or is subject (in whole or in part) to a jury trial. To the fullest extent permitted
by law, the parties hereby agree that the mailing of process and other papers in connection with any such action or proceeding in the
manner provided by Section 21 or in such other manner as may be permitted by law, shall be valid and sufficient service thereof.

 

    17 

     

    

 

23.            Identical
counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an
original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against
whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 

24.            Miscellaneous.
Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs
of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction
thereof.

 

25.            Period
of limitations. No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against
Indemnitee, Indemnitee’s spouse, heirs, executors or personal or legal representatives after the expiration of two (2) years
from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released
unless asserted by the timely filing of a legal action within such two-year period; provided, however, that if any shorter
period of limitations is otherwise applicable to any such cause of action such shorter period shall govern.

 

26.            Additional
acts. If for the validation of any of the provisions in this Agreement any act, resolution, approval or other procedure is required
to the fullest extent permitted by law, the Company undertakes to cause such act, resolution, approval or other procedure to be affected
or adopted in a manner that will enable the Company to fulfill its obligations under this Agreement.

 

27.            Waiver
of claims to trust account. Notwithstanding anything contained herein to the contrary, Indemnitee hereby agrees that it does
not have any right, title, interest or claim of any kind (each, a “Claim”) in or to any monies in the trust account established
in connection with the Company’s initial public offering for the benefit of the Company and holders of shares issued in such offering,
and hereby waives any Claim it may have in the future as a result of, or arising out of, any services provided to the Company and will
not seek recourse against such trust account for any reason whatsoever. Accordingly, Indemnitee acknowledges and agrees that any
indemnification provided hereto will only be able to be satisfied by the Company if (i) the Company has sufficient funds outside
of the Trust Account to satisfy its obligations hereunder or (ii) the Company consummates a Business Combination.

 

28.            Maintenance
of Insurance. The Company shall use commercially reasonable efforts to obtain and maintain in effect during the entire period for
which the Company is obligated to indemnify the Indemnitee under this Agreement, one or more policies of insurance with reputable insurance
companies to provide the officers/directors of the Company with coverage for losses from wrongful acts and omissions and to ensure the
Company’s performance of its indemnification obligations under this Agreement. The Indemnitee shall be covered by such policy or
policies in accordance with its or their terms to the maximum extent of the coverage available for any such director or officer under
such policy or policies. In all such insurance policies, the Indemnitee shall be named as an insured in such a manner as to provide the
Indemnitee with the same rights and benefits as are accorded to the most favorably insured of the Company’s directors and officers.

 

    18 

     

    

 

29.            Interpretation.

 

	 	In this Agreement:

 

	 	(a)	“written” and “in writing” include all modes of representing or reproducing words in visible form, including in the form of an Electronic Record;
	 	(b)	“shall” shall be construed as imperative and “may” shall be construed as permissive;
	 	(c)	references to provisions of any law or regulation shall be construed as references to those provisions as amended, modified, re-enacted or replaced;
	 	(d)	any phrase introduced by the terms “including”, “include”, “in particular” or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms;
	 	the term “and/or” is used herein to mean both “and” as well as “or. ” The use of “and/or” in certain contexts in no respects qualifies or modifies the use of the terms “and" or “or" in others. The term "or" shall not be interpreted to be exclusive and the term “and” shall not be interpreted to require the conjunctive (in each case, unless the context otherwise requires).

 

[Signature Page Follows]

 

    19 

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Indemnification Agreement to be signed as of the day and year first above written.

 

	 	PepperLime Health Acquisition Corporation
	 	 
	 	By:	 
	 	 	Name: Eran Pilovsky
	 	 	Title: Chief Financial Officer
	 	 	 
	 	INDEMNITEE
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	Address:
	 	 	 
	 	c/o PepperLime Health Acquisition Corporation
	 	548 Market Street, Suite 97425
	 	San Francisco, California 94104

 

[Signature Page to Indemnification
Agreement]Exhibit 10.8

 

[Date], 2021

 

[Anchor Investors]

[Address]

 

	Attn:	[·]

 

	RE:	Anchor Investment Agreement

 

Dear [Insert Name]:

 

This agreement (the
“Agreement”) is entered into
on [·], 2021 by and among the undersigned investor(s) (on a several and not a joint
and several basis) (each, an “Investor”
and collectively, the “Investors”; provided that if there is only one Investor, all references to Investors shall
be deemed to be in the singular), PepperOne LLC, a Cayman Islands limited liability company (the “Sponsor”),
and PepperLime Health Acquisition Corporation, a newly incorporated blank check company, incorporated as a Cayman Islands exempted
company with limited liability (the “Company”).
Pursuant to the terms hereof, the Sponsor hereby accepts the offer the Investors have made to purchase [•] shares of Class B
ordinary shares, $0.0001 par value per share of the Company (the “Shares”),
all of which are subject to forfeiture by each Investor if such Investor does not submit an indication of interest in the initial
public offering (“IPO”) of
units (“Units”) of the
Company. All references in this Agreement to Shares being forfeited shall take effect as surrenders for no consideration of such
Shares as a matter of Cayman Islands law. The Company, the Sponsor’s and the Investors’ agreements regarding such Shares
are as follows:

 

1.       Purchase
of Securities.

 

1.1       Purchase
of Shares. For the sum of $[·] (the “Purchase
Price”), which the Sponsor acknowledges receiving in cash, the Sponsor hereby transfers the number of Shares set forth
on the signature or schedule hereto with respect to such Investor, and each such Investor hereby purchases such Shares from the Sponsor,
subject to forfeiture, on the terms and subject to the conditions set forth in this Agreement.

 

Concurrently with
each Investor’s execution of this Agreement, the Company shall effect issuance of the Shares in book-entry form and provide each
Investor with a copy of the Company's register of members evidencing the issuance of such Shares.

 

2.       Representations,
Warranties and Agreements.

 

2.1       Investors’
Representations, Warranties and Agreements. To induce the Sponsor to transfer the Shares to each Investor, each Investor hereby represents
and warrants to the Sponsor and the Company and agrees with the Sponsor and the Company as follows:

 

     

    2 | 14

    

 

2.1.1       No
Government Recommendation or Approval. Such Investor understands that no federal or state agency has passed upon or made any recommendation
or endorsement of the offering of the Shares.

 

2.1.2       No
Conflicts. The execution, delivery and performance of this Agreement and the consummation by such Investor of the transactions contemplated
hereby do not violate, conflict with or constitute a default under (i) the formation and governing documents of the Investor, (ii) any
agreement, indenture or instrument to which the Investor is a party or (iii) any law, statute, rule or regulation to which the Investor
is subject, or any agreement, order, judgment or decree to which such Investor is subject.

 

2.1.3       Organization
and Authority. Such Investor is duly organized, validly existing, and in good standing under the laws of the jurisdiction of its formation
and has all requisite power and authority to carry on its business as presently conducted and as proposed to be conducted. Such Investor
possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement. Upon execution and
delivery by such Investor and the other parties hereto, this Agreement is a legal, valid and binding agreement of such Investor, enforceable
against such Investor in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency,
fraudulent conveyance or similar laws affecting the enforcement of creditors’ rights generally and subject to general principles
of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

 

2.1.4       Experience,
Financial Capability and Suitability. Such Investor is: (i) sophisticated in financial matters and is able to evaluate the risks and
benefits of the investment in the Shares and (ii) able to bear the economic risk of its investment in the Shares for an indefinite period
of time because the Shares have not been registered under the Securities Act (as defined below) and therefore cannot be sold unless subsequently
registered under the Securities Act or an exemption from such registration is available. Such Investor is capable of evaluating the merits
and risks of its investment in the Company and has the capacity to protect its own interests. Investor must bear the economic risk of
this investment until the Shares are sold pursuant to: (i) an effective registration statement under the Securities Act or (ii) an exemption
from registration available with respect to such sale. Such Investor is able to bear the economic risks of an investment in the Shares
and to afford a complete loss of Investor’s investment in the Shares.

 

2.1.5       Access
to Information; Independent Investigation. Prior to the execution of this Agreement, such Investor has had the opportunity to
ask questions of and receive answers from representatives of the Company concerning an investment in the Company, as well as the
finances, operations, business and prospects of the Company, and the opportunity to obtain additional information to verify the
accuracy of all information so obtained. In determining whether to make this investment, such Investor has relied solely on
Investor’s own knowledge and understanding of the Company and its business based upon Investor’s own due diligence
investigation and the information furnished pursuant to this paragraph or as described in this paragraph. Such Investor understands
that no person has been authorized to give any information or to make any representations which were not furnished pursuant to or as
described in this Section 2, and such Investor has not relied on any other representations or information in making its investment
decision, whether written or oral, relating to the Company, its operations and/or its prospects.

 

     

    3 | 14

    

 

2.1.6       Regulation
D Offering. Such Investor represents that it is an “accredited investor” as such term is defined in Rule 501(a) of Regulation
D under the Securities Act of 1933, as amended (the “Securities
Act”) and acknowledges the sale contemplated hereby is being made in reliance on a private placement exemption to “accredited
investors” within the meaning of Section 501(a) of Regulation D under the Securities Act or similar exemptions under state law.

 

2.1.7       Investment
Purposes. Such Investor is purchasing the Shares solely for investment purposes, for such Investor’s own account and not for
the account or benefit of any other person, and not with a view towards the distribution or dissemination thereof. Such Investor did not
decide to enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule 502 under
the Securities Act.

 

2.1.8       Restrictions
on Transfer; Shell Company. Such Investor understands the Shares are being offered in a transaction not involving a public
offering within the meaning of the Securities Act. Such Investor understands the Shares will be “restricted securities”
within the meaning of Rule 144(a)(3) under the Securities Act, and such Investor understands that the certificates or book-entries
representing the Shares will contain a legend in respect of such restrictions. If in the future such Investor decides to offer,
resell, pledge, charge or otherwise transfer the Shares, such Shares may be offered, resold, pledged, charged or otherwise
transferred only pursuant to: (i) registration under the Securities Act, or (ii) an available exemption from registration. Such
Investor agrees that if any transfer of its Shares or any interest therein is proposed to be made, as a condition precedent to any
such transfer, such Investor may be required to deliver to the Company customary representations reasonably satisfactory to the
Company. Absent registration or an exemption, such Investor agrees not to resell the Shares. Such Investor further acknowledges that
because the Company is a shell company, Rule 144 may not be available to such Investor for the resale of the Shares until one year
following consummation of the initial business combination of the Company, despite technical compliance with the requirements of
Rule 144 and the release or waiver of any contractual transfer restrictions.

 

     

    4 | 14

    

 

2.1.9       No
Governmental Consents. No governmental, administrative or other third party consents or approvals are required, necessary or appropriate
on the part of such Investor in connection with the transactions contemplated by this Agreement.

 

2.1.10       Foreign
Corrupt Practices and Compliance with Anti-Money Laundering Laws. Such Investor is not, and is not acting as, an agent, representative,
intermediary or nominee for any person identified on the list of blocked persons maintained by the Office of Foreign Assets Control of
the US Treasury Department; and such Investor has complied with all applicable US laws, regulations, directives and executive orders relating
to anti-money laundering.

 

2.1.11       Legal
Action. Such Investor has never been suspended or expelled from membership in any securities or commodities exchange or association
or had a securities or commodities license or registration denied, suspended or revoked. Such Investor is not subject to or a respondent
in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain from any act or practice
relating to the offering of securities in any jurisdiction; it, he or she has never been convicted of, or pleaded guilty to, any crime
(i) involving fraud, (ii) relating to any financial transaction or handling of funds of another person, or (iii) pertaining to any dealings
in any securities and it, he or she is not currently a defendant in any such criminal proceeding.

 

2.2       Company’s
Representations, Warranties and Agreements. To induce each Investor to purchase the Shares, the Company hereby represents and warrants
to each Investor and agrees with each Investor as follows:

 

2.2.1       Corporate
Power. The Company possesses all requisite corporate power and authority necessary to enter into this Agreement and to carry out the
transactions contemplated by this Agreement. Upon execution and delivery by the Company and the other parties hereto, this Agreement is
a legal, valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, fraudulent conveyance or similar laws affecting the enforcement of creditors’
rights generally and subject to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in
equity).

 

2.2.2       No
Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Company of the transactions contemplated
hereby do not violate, conflict with or constitute a default under (i) the amended and restated memorandum and articles of association
of the Company, (ii) any agreement, indenture or instrument to which the Company is a party or by which the Shares are bound or (iii)
any law, statute, rule or regulation to which the Company is or the Shares are subject, or any agreement, order, judgment or decree to
which the Company is or the Shares are subject.

 

     

    5 | 14

    

 

2.2.3       No
Adverse Actions. There are no actions, suits, investigations or proceedings pending, threatened against or affecting the Company or
the Shares which: (i) seek to restrain, enjoin, prevent the consummation of or otherwise affect the transactions contemplated by this
Agreement or (ii) question the validity or legality of any transactions or seeks to recover damages or to obtain other relief in connection
with any transactions.

 

2.2.4       Title.
The Shares (i) are owned of record and beneficially by the Sponsor, free and clear of all encumbrances, and (ii) upon consummation of
the transactions contemplated by this Agreement, each Investor shall own and receive good title to the Shares, free and clear of all liens,
pledges, security interests, charges, claims, encumbrances, agreements, options, voting trusts, proxies and other arrangements or restrictions
of any kind, except, in the case of each of clauses (i) and (ii) hereof, as otherwise agreed herein, those arising under applicable securities
laws or as otherwise disclosed in the Registration Statement (as defined below).

 

2.3       Sponsor’s
Representations, Warranties and Agreements. To induce each Investor to purchase the Shares, the Sponsor hereby represents and warrants
to each Investor and agrees with each Investor as follows:

 

2.3.1       Power.
The Sponsor possesses all requisite power and authority necessary to enter into this Agreement and to carry out the transactions contemplated
by this Agreement. Upon execution and delivery by the Sponsor and the other parties hereto, this Agreement is a legal, valid and binding
agreement of the Sponsor, enforceable against the Sponsor in accordance with its terms, except as such enforceability may be limited by
applicable bankruptcy, insolvency, fraudulent conveyance or similar laws affecting the enforcement of creditors’ rights generally
and subject to general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

 

2.3.2       No
Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Sponsor of the transactions contemplated
hereby do not violate, conflict with or constitute a default under (i) the Limited Liability Company Agreement of the Sponsor, (ii) any
agreement, indenture or instrument to which the Sponsor is a party or by which the Shares are bound or (iii) any law, statute, rule or
regulation to which the Sponsor or the Shares are subject, or any agreement, order, judgment or decree to which the Sponsor is or the
Shares are subject.

 

     

    6 | 14

    

 

2.3.3       No
Adverse Actions. There are no actions, suits, investigations or proceedings pending, threatened against or affecting the Sponsor which:
(i) seek to restrain, enjoin, prevent the consummation of or otherwise affect the transactions contemplated by this Agreement or (ii)
question the validity or legality of any transactions or seeks to recover damages or to obtain other relief in connection with any transactions.

 

2.3.4       Issuance.
The Shares, when issued to the Sponsor, were duly authorized and validly issued, fully paid and non-assessable, free and clear of
all liens, pledges, security interests, charges, claims, encumbrances, agreements, options, voting trusts, proxies and other arrangements
or restrictions of any kind, other than those arising under applicable securities laws or as otherwise disclosed in the Registration Statement
and were not issued in violation of, or subject to, any preemptive or similar rights.

 

2.3.5       Most
Favored Nation. Substantially concurrently with the execution of this Agreement, the Sponsor is entering into separate agreements
with other “anchor investors” in respect of indications of interest in purchasing units in the IPO. The Sponsor represents
that the material terms of such other agreements (both economic and non-economic) are not more favorable to such other “anchor investors”
thereunder than the terms of this Agreement. In the case that another “anchor investor” is afforded more favorable terms than
the Investors, the Sponsor shall promptly notify each Investor of such more favorable terms, and the Investors shall have the right to
elect to have such more favorable terms, so as to be on the same terms, in which case the parties hereto shall promptly amend this Agreement
to effect the same. For the avoidance of doubt, if any other “anchor investor” has an ability to purchase proportionately
more Shares relative to its expression of interest in the IPO than the Investors, then such other “anchor investor” shall
be considered to have more favorable material terms than the Investors. Notwithstanding the foregoing, this provision does not apply to
any investor that (i) participates in the at-risk capital of the Sponsor via a more than de minimis investment or co-sponsorship
or (ii) enters into a forward purchase agreement in connection with a private investment in public equity (PIPE) in support of the SPAC’s
potential business combination.

 

3.       Forfeiture
of Shares.

 

3.1       Indication
of Interest. The Investors have expressed an interest in acquiring up to [·]% of
the Units (the “Indicated Percentage”) offered in the IPO, or [·]
Units assuming 15,000,000 Units are offered in the IPO, without giving effect to any exercise of the underwriters’ over-allotment
option (such Units, the “Indicated Units”). In the event that the Investors submit an order to the underwriters of
less than the Indicated Percentage of the base deal size of 15,000,000 Units to be sold in the IPO, the Investors acknowledge and agree
that they (or, if applicable, it and any transferees of Shares) shall forfeit back to the Sponsor (pro rata on the basis of the number
of Shares such Investor is to acquire) any and all rights to a number of Shares equal to (i) the number of Shares purchased pursuant
to this Agreement, multiplied by (ii) (x) the Indicated Percentage minus the percentage of Units sold in the IPO Investor actually subscribed
for, divided by (y) the Indicated Percentage. For the avoidance of doubt, the number of Shares to be forfeited shall be calculated based
on the number of Units subscribed for prior to any cutbacks made by the underwriters in the IPO. The parties hereto acknowledge that
in the event the Investors or their affiliates do not submit an order to the underwriters in the IPO for at least the number of Indicated
Units, the Sponsor and the Company’s only remedy with respect thereto shall be the forfeiture of such Investor’s Shares.

 

     

    7 | 14

    

 

3.2       Investor
Participation. The Investors shall not be required to participate in any upsizing above the base deal size of $150,000,000 nor any
over-allotment exercise. The Investors’ allocation of Shares shall not be reduced should the Investors be allocated less than the
Indicated Percentage Units to be sold in the IPO.

 

3.3       Termination
of Rights as Shareholder. If any of the Shares are forfeited in accordance with this Section 3, then after such time the Investors
(or any successor in interest), shall no longer have any rights as a holder of such forfeited Shares.

 

3.4       Share
Adjustments. In the event of any adjustment in the number of Shares is required pursuant to this Section 3, the book-entry records
for such Shares shall be reduced accordingly. If the Shares are required to be issued in certificated form (such certificates hereinafter
referred to as the “Original Certificates”)
an adjustment to the Original Certificates, if any, is required pursuant to this Section 3, then the Investors shall return such Original
Certificates to the Company or its designated agent as soon as practicable upon its receipt of notice from the Company advising each Investor
of such adjustment, following which a new certificate (the “New
Certificate”), if any, shall be issued in such amount representing the adjusted number of Shares held by each Investor.
The New Certificate, if any, shall be returned to the Investors as soon as practicable. Any such adjustment for any uncertificated securities
held by the Investors shall be made in book-entry form.

 

3.5       Change
in Investment. The Shares directly or indirectly owned by the Investors shall not be subject to forfeitures, surrenders, claw-backs,
transfers, disposals, exchanges or share price vesting triggers commonly known as “earn-outs” for any reason, including as
part of negotiating a business combination.

 

4.       Waiver
of Liquidation Distributions; Redemption Rights. Solely with respect to the Shares purchased pursuant to this Agreement, each Investor
hereby waives any and all right, title, interest or claim of any kind (“Claim”)
in or to any distributions by the Company from the trust account which will be established for the benefit of the Company’s public
shareholders and into which substantially all of the proceeds of the IPO will be deposited (the “Trust
Account”), in the event of a liquidation of the Company upon the Company’s failure to timely complete an initial
business combination. Further, in no event will the Investors have the right to redeem any Shares into funds held in the Trust Account
upon the successful completion of an initial business combination. In the event any Investor has any Claim against the Company under
this Agreement, the Investors shall pursue such Claim solely against the Company and its assets outside the Trust Account and not against
the property or any monies in the Trust Account. The Investors are not waiving any redemption right or claim to funds held in the trust
account for shares or units purchased in the IPO or aftermarket. In the event any Investor purchases ordinary shares or units in the
IPO or in the aftermarket, any ordinary shares or units so purchased shall be eligible to receive any liquidating distributions by the
Company and will have the right to redeem or tender any such ordinary shares into funds held in the Trust Account upon the successful
completion of an initial business combination, or any other event that affords public shareholders the right to redeem.

 

     

    8 | 14

    

 

5.       Restrictions
on Transfer.

 

5.1       Securities
Law Restrictions. In addition to any restrictions to be contained in that certain letter agreement (commonly known as an “Insider
Letter”) to be dated as of the closing of the IPO by and between the Investors and the Company, each Investor agrees
not to sell, transfer, pledge, charge, hypothecate or otherwise dispose of (“Transfer”) all or any part of the Shares
unless, prior thereto (a) a registration statement on the appropriate form under the Securities Act with respect to the Shares proposed
to be Transferred shall then be effective or (b) the Company has received an opinion from counsel reasonably satisfactory to the Company,
that such registration is not required because such transaction is exempt from registration under the Securities Act and the rules promulgated
by the Securities and Exchange Commission thereunder. This Section 5.1 shall not apply to any Transfer by the Investor to any Permitted
Transferee (as defined in the Insider Letter).

 

5.2       Lock-up.
Each Investor acknowledges that the Shares will be subject to lock-up provisions (the “Lock-up”)
contained in the Insider Letter. Notwithstanding the foregoing and for the sake of clarification, the "Lock-up" is not applicable
to shares, warrants or units purchased by any Investor in the IPO or aftermarket (such shares, warrants or units as applicable,  "Investor
Securities") and each Investor has made no representation or commitment with respect to holding any such Investor Securities
for any duration.

 

5.3       Restrictive
Legends. Each register and book-entry for the Shares shall contain a notation, and each certificate (if any) representing the Shares
shall have endorsed thereon legends, substantially as follows:

 

“THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY
INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED, CHARGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL,
IS AVAILABLE.”

 

     

    9 | 14

    

 

“THE SECURITIES REPRESENTED BY
THIS CERTIFICATE ARE SUBJECT TO A LOCKUP AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, CHARGED OR OTHERWISE DISPOSED DURING THE
TERM OF THE LOCKUP.”

 

5.4       Additional
Shares or Substituted Securities. In the event of the declaration of a share dividend, the declaration of an extraordinary dividend
payable in a form other than Shares, a spin-off, a share split, an adjustment in conversion ratio, a recapitalization or a similar transaction
affecting the Company’s outstanding Shares without receipt of consideration, any new, substituted or additional securities or other
property which are by reason of such transaction distributed with respect to any Shares subject to this Section 5 or into which such Shares
thereby become convertible shall immediately be subject to this Section 5 and Section 3. Appropriate adjustments to reflect the distribution
of such securities or property shall be made to the number and/or class of Shares subject to this Section 5 and Section 3.

 

5.5       Registration
Rights. Each Investor acknowledges that the Shares are being purchased pursuant to an exemption from the registration requirements
of the Securities Act and will become freely tradable only after certain conditions are met or they are registered pursuant to a registration
rights agreement to be entered into with the Company prior to the closing of the IPO, which registration rights shall be made available
by the Company to each Investor on terms no less favorable than those afforded to any other pre-IPO investor in the Company.

 

6.       Other
Agreements.

 

6.1       Further
Assurances. The parties agree to execute such further instruments and to take such further action as may reasonably be necessary to
carry out the intent of this Agreement.

 

6.2       Notices.
All notices, statements or other documents which are required or contemplated by this Agreement shall be: (a) in writing and delivered
personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission to
the address designated in writing and (b) by electronic mail, to the electronic mail address most recently provided to such party or
such other electronic mail address as may be designated in writing by such party. Any notice or other communication so transmitted shall
be deemed to have been given (i) on the day of delivery, if delivered personally, (ii) at the time of transmission if sent by electronic
mail, as long as the sender does not receive an automated message that the transmission was not delivered, (iii) one (1) business day
after delivery to an overnight courier service or (iv) five (5) days after mailing if sent by mail.

 

     

    10 | 14

    

 

6.3       Entire
Agreement. This Agreement, together with the Insider Letter and the Registration Rights Agreement, each substantially in the form
to be filed as an exhibit to the Registration Statement on Form S-1 associated with the Company’s IPO (“Registration
Statement”), embodies the entire agreement and understanding between the Investors, the Sponsor and the Company with
respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter
hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect,
or be used to interpret, change or restrict, the express terms and provisions of this Agreement.

 

6.4       Modifications
and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by all parties
hereto.

 

6.5       Waivers
and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by a
written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed
to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar.
Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not
constitute a continuing waiver or consent.

 

6.6       Assignment.
The rights and obligations under this Agreement may not be assigned by either party hereto without the prior written consent of the other
party.

 

6.7       Benefit. 
All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and
shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall
be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a
third-party beneficiary of this Agreement.

 

6.8       Governing
Law.   This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by
the laws of the State of New York applicable to contracts wholly performed within the borders of such state, without giving effect to
the conflict of law principles thereof.

 

6.9       Severability.
In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in this
Agreement shall be unreasonable or unenforceable in any respect, then such provision shall be deemed limited to the extent that such
court deems it reasonable and enforceable, and as so limited shall remain in full force and effect. In the event that such court shall
deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain
in full force and effect.

 

     

    11 | 14

    

 

6.10       No
Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement,
and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of such party. No single
or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps
to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any
other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of such
party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle
the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver
of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.

 

6.11       Survival
of Representations and Warranties. All representations and warranties made by the parties hereto in this Agreement or in any other
agreement, certificate or instrument provided for or contemplated hereby, shall survive the execution and delivery hereof and any investigations
made by or on behalf of the parties and the consummation of the transactions contemplated by this Agreement.

 

6.12       No
Broker or Finder. Each of the parties hereto represents and warrants to the other that no broker, finder or other financial consultant
has acted on its behalf in connection with this Agreement or the transactions contemplated hereby in such a way as to create any liability
on the other. Each of the parties hereto agrees to indemnify and save the other harmless from any claim or demand for commission or other
compensation by any broker, finder, financial consultant or similar agent claiming to have been employed by or on behalf of such party
and to bear the cost of legal expenses incurred in defending against any such claim.

 

6.13       Headings
and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall
in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

6.14       Counterparts.
This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that
both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or any other
form of electronic delivery, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such signature page were an original thereof.

 

     

    12 | 14

    

 

6.15       Construction.
The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of intent
or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of
proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement. The words “include,”
 “includes,” and “including” will be deemed to be followed by “without limitation.” Pronouns in masculine,
feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be construed to include
the plural and vice versa, unless the context otherwise requires. The words “this Agreement,” “herein,” “hereof,”
 “hereby,” “hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular
subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will
have independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect,
the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative
levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in
breach of the first representation, warranty, or covenant.

 

6.16       Disclosure.
Neither the SPAC nor Sponsor nor any affiliate thereof shall disclose the identity of the Investors or their affiliates or principals
(in any regulatory filing or otherwise), except as required by any applicable statute, law, ordinance, regulation, rule, code, order,
common law, judgment, decree, other requirement or rule of law of any federal, state, local or foreign government or political subdivision
thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental
regulatory authority or quasigovernmental authority, or any arbitrator, court or tribunal of competent jurisdiction (a “Governmental
Authority”) or in connection with any inquiry by a Governmental Authority (including, without limitation, any questions or comments
from the US Securities and Exchange Commission (the “SEC”) or the staff of the SEC), without the prior consent of such
Investor. The parties hereto further agree that Paragraph 9(b) of the Insider Letter does not apply to the Investors.

 

6.17       Jurisdiction.
The parties hereby irrevocably and unconditionally (i) submit to the jurisdiction of the state courts of New York and the United States
District Court for the Southern District of New York for the purpose of any suit, action or other proceeding arising out of or based
upon this Agreement, (ii) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except
in state courts of New York or the United States District Court for the Southern District of New York, and (iii) waive, and agree not
to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally
to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action
or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement
or the subject matter hereof may not be enforced in or by such court.

 

     

    13 | 14

    

 

6.18       Waiver
of Jury Trial. The parties hereto hereby waive any right to a jury trial in connection with any litigation pursuant to this Agreement
and the transactions contemplated hereby.

 

6.19       Expenses.
Each of the Company, the Sponsor and the Investors will bear its own costs and expenses incurred in connection with the preparation, execution
and performance of this Agreement and the consummation of the transactions contemplated hereby, including all fees and expenses of agents,
representatives, financial advisors, legal counsel and accountants. The Company shall be responsible for the fees of its transfer agent,
stamp taxes and all of The Depository Trust Company’s fees associated with the issuance of the Shares and the securities issuable
upon conversion or exercise of the Shares.

 

6.20       Specific
Performance. Each party hereto agrees that irreparable damage may occur in the event any provision of this Agreement was not performed
by any of the other parties hereto in accordance with the terms hereof and that the such party shall be entitled to seek specific performance
of the terms hereof, in addition to any other remedy at law or equity.

 

6.21       Confidentiality.
Except as may be required by law, regulation or applicable stock exchange listing requirements, unless and until the transactions contemplated
hereby and the terms hereof are publicly announced or otherwise publicly disclosed by the Company, the parties hereto shall keep confidential
and shall not publicly disclose the existence or terms of this Agreement.

 

6.22       No
Material Non-Public Information. The Company and the Sponsor agree that none of the information conveyed to the Investors in connection
with this Agreement and transactions contemplated hereby will constitute material non-public information of the Company or of its securities
upon the effectiveness of the Registration Statement.

 

6.23       Obligations
not Joint and Several. The obligations of each Investor under this Agreement and those obligations of any other investor that signs
an anchor investment agreement (each, an “Other Investor”) are several and not joint and several, and each Investor
shall not be responsible in any way for the performance of the obligations of any Other Investor under any such other agreement. Nothing
contained in this Agreement, and no action taken by the Investors pursuant hereto, shall be deemed to constitute the Investors and Other
Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors and
the Other Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated
by this Agreement and the Company acknowledges that the Investors and the Other Investors are not acting in concert or as a group with
respect to such obligations or the transactions contemplated by this Agreement or any other agreement. The Company and each Investor
confirm that each Investor has independently participated in the negotiation of the transactions contemplated hereby with the advice
of its own counsel and advisors. Each Investor shall be entitled to independently protect and enforce its rights, including, without
limitation, the rights arising out of this Agreement, and it shall not be necessary for any Other Investor to be joined as an additional
party in any proceeding for such purpose.

 

     

    14 | 14

    

 

7.       Voting
and Tender of Shares. Each Investor agrees with the Company to vote the Shares in favor of an initial business combination that the
Company negotiates and submits for approval to the Company’s shareholders and shall not seek redemption with respect to such Shares.
Additionally, each Investor agrees with the Company not to tender any Shares in connection with a tender offer presented to the Company’s
shareholders in connection with an initial business combination negotiated by the Company. The agreements set forth in this paragraph
arise solely between each Investor and the Company, and the Sponsor shall have no right to enforce the agreements made in this paragraph
or seek damages or any other remedy in connection with any alleged breach hereof. For purposes of clarity, in the event any Investor purchases
Class A ordinary shares or Units in the IPO or in the aftermarket, such Investor retains the right to tender any additional shares of
Class A ordinary shares so purchased in connection with a tender offer.

 

8.       Indemnification.
Each party shall indemnify the other against any loss, cost or damages (including reasonable attorney’s fees and expenses) incurred
as a result of such party’s breach of any representation, warranty, covenant or agreement in this Agreement.

 

9.       Termination.
This Agreement shall terminate on the earliest of (i) the expiration of the Lock-Up pursuant to the Insider Letter, (ii) the liquidation
of the Company, (iii) written notice from the Company that the IPO has been abandoned, and (iv) if the IPO has not priced by October
31, 2021, unless, in each case, otherwise agreed in writing by the parties hereto. In the event of any termination of this agreement
pursuant to clause (ii), (iii) or (iv) of the preceding sentence, each Investor acknowledges and agrees that it (or, if applicable, it
and any transferees of Shares) shall forfeit all Shares back to the Sponsor.

 

[Signature Page Follows]

 

     

     

    

 

If the foregoing accurately sets
forth our understanding and agreement, please sign the enclosed copy of this Agreement and return it to us.

 

	Very truly yours,	 	 
	 	 	 
	PEPPERLIME HEALTH	)	 	 
	ACQUISITION CORPORATION	)	 	 
	 	 	 
	By:	 	 
	 	 	 
	Name:	 	 	 
	 	 	 
	Title:	 	 	 
	 	 	 
	Accepted and agreed as of the date first written above.	 	 
	 	 	 
	PEPPERONE LLC	 	)	 	 
	 	 	 
	By:	 	 
	 	 	 
	Name:	 	 	 
	 	 	 
	Title:	 	 	 
	 	 	 
	[INVESTOR]	 	)	 	 
	 	 	 
	By:	 	 
	 	 	 
	Name:	 	 	 
	 	 	 
	Title:	 	 	 
	 	 	 
	Number of Shares:	 	 	 
	 	 	 
	Price:	 	 	 
	 	 	 
	[INVESTOR]	 	)	 	 
	 	 	 
	By:	 	 
	 	 	 
	Name:	 	 	 
	 	 	 
	Title:	 	 	 
	 	 	 
	Number of Shares:	 	 	 
	 	 	 
	Price:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]